Overview

A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro

Status:
Completed

Trial end date:
2008-12-01

Target enrollment:

Participant gender:

Summary

28 subjects to be enrolled for a screening period, 3 dosing visits & a follow-up visit. Visits 2 and 3 dosing of TI Inhalation Powder, cross over between two 15 U cartridges and one 30 U cartridge. Visit 4 dosing will be a sc injection of 10 IU of RAA (rapid-acting insulin analogue).

Phase:

Phase 2

Details

Lead Sponsor:

Mannkind Corporation

Treatments:

Insulin
Insulin Lispro
Insulin, Globin Zinc